432 related articles for article (PubMed ID: 29958605)
21. [Hearing loss caused by high dose carboplatin therapy].
Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
[TBL] [Abstract][Full Text] [Related]
23. Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment.
Robertson MS; Hayashi SS; Camet ML; Trinkaus K; Henry J; Hayashi RJ
Pediatr Blood Cancer; 2019 Jan; 66(1):e27494. PubMed ID: 30334605
[TBL] [Abstract][Full Text] [Related]
24. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
Clemens E; de Vries AC; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; Pluijm SF; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; Neggers SJ; van Grotel M; M van den Heuvel-Eibrink M
Pediatr Hematol Oncol; 2017 Mar; 34(2):120-129. PubMed ID: 28590156
[TBL] [Abstract][Full Text] [Related]
25. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
26. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma.
Musial-Bright L; Fengler R; Henze G; Hernáiz Driever P
Childs Nerv Syst; 2011 Mar; 27(3):407-13. PubMed ID: 20931205
[TBL] [Abstract][Full Text] [Related]
27. Ototoxicity monitoring in children treated with platinum chemotherapy.
Brooks B; Knight K
Int J Audiol; 2018 Sep; 57(sup4):S34-S40. PubMed ID: 28737048
[TBL] [Abstract][Full Text] [Related]
28. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
Dillard LK; Lopez-Perez L; Martinez RX; Fullerton AM; Chadha S; McMahon CM
Cancer Epidemiol; 2022 Aug; 79():102203. PubMed ID: 35724557
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Risk Factors Causing Ototoxicity in Childhood Cancers Located in the Head and Neck Region Treated With Platinum-based Chemotherapy.
Olgun Y; Çakir Kizmazoğlu D; İnce D; Ellidokuz H; Güneri EA; Olgun N; Kirkim G
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e930-e934. PubMed ID: 33885038
[TBL] [Abstract][Full Text] [Related]
30. Incidence of childhood hearing loss after in utero exposure to platinum agents.
Finch LE; Cardonick EH
Prenat Diagn; 2021 Oct; 41(11):1467-1474. PubMed ID: 34462927
[TBL] [Abstract][Full Text] [Related]
31. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
32. Long-term audiologic follow-up of carboplatin-treated children with retinoblastoma.
Geurtsen ML; Kors WA; Moll AC; Smits C
Ophthalmic Genet; 2017; 38(1):74-78. PubMed ID: 27050825
[TBL] [Abstract][Full Text] [Related]
33. Ototoxic impact of cisplatin in pediatric oncology patients.
Berg AL; Spitzer JB; Garvin JH
Laryngoscope; 1999 Nov; 109(11):1806-14. PubMed ID: 10569412
[TBL] [Abstract][Full Text] [Related]
34. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469
[TBL] [Abstract][Full Text] [Related]
35. Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-655. PubMed ID: 27811606
[TBL] [Abstract][Full Text] [Related]
36. Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer.
Bass JK; Hua CH; Huang J; Onar-Thomas A; Ness KK; Jones S; White S; Bhagat SP; Chang KW; Merchant TE
J Clin Oncol; 2016 Apr; 34(11):1248-55. PubMed ID: 26811531
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
[TBL] [Abstract][Full Text] [Related]
38. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
39. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
40. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
